Examples of studies designed to inhibit protein–protein interactions in order to prevent cancer progression are as follows: (1) An inhibitor of the interactions of bromodomain and extra-terminal family member BRD4 with other proteins in an incurable subtype of human squamous carcinoma [130]; (2) a competitor of the pro-survival protein Bcl-XL [131]; (3) an inhibitor that interferes with binding of MDM2 to P53 [132]; and (4) an inhibitor that blocks the binding of VEGF to its receptor to prevent angiogenesis [133]. Here, VEGFA is linked to cancer.